Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00890526 · ClinicalTrials.gov registry record · Phase 1
Intervention for Reduced Sound Tolerance
A Phase 1 study, sponsored by University of Alabama, Tuscaloosa.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00890526: Completed Phase 1 study, sponsored by University of Alabama, Tuscaloosa.
NCT00890526 is a Phase 1 study that has completed, run by University of Alabama, Tuscaloosa. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00890526, a Phase 1 study, has completed, sponsored by University of Alabama, Tuscaloosa.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
Hyperacusis is the intolerance to sound levels that normally are judged acceptably loud to others. The presence of hyperacusis (diagnosed or undiagnosed) can be an important reason why some persons reject amplified sound from hearing aids. Tinnitus Retraining Therapy (TRT), originally proposed for the treatment of persons with debilitating tinnitus, offers the significant secondary benefit of increased Loudness Discomfort Levels (LDLs), along with expansion of the dynamic range for loudness. TRT uses both counseling and sound therapy from daily exposure to soft sound from bilateral noise generator devices (NGs) and has been promoted as an intervention for hyperacusis. The hypothesis of this investigational study is that the counseling and sound therapy principles used in TRT can be applied successfully to treat hearing-impaired hearing-aid candidates with reduced sound tolerance who are otherwise should benefit from hearing aids.
Interventions
- OTHER Sound Therapy (Tinnitus Retraining Therapy)
- OTHER Counseling (Tinnitus Retraining Therapy)
- OTHER No Counseling
- OTHER Placebo Sound Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2002-07 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
What the finished NCT00890526 record still lists
NCT00890526 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 4 interventions - of which Sound Therapy (Tinnitus Retraining Therapy) is the first listed.
NCT00890526 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00890526 about?
NCT00890526 is a clinical study titled "Intervention for Reduced Sound Tolerance". Hyperacusis is the intolerance to sound levels that normally are judged acceptably loud to others. The presence of hyperacusis (diagnosed or undiagnosed) can be an important reason why some persons reject amplified sound from hearing aids. Tinnitus Retraining Therapy (TRT), originally proposed for t...
What is the current status of trial NCT00890526?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2002-07. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00890526?
The interventions under investigation include: Sound Therapy (Tinnitus Retraining Therapy) (OTHER), Counseling (Tinnitus Retraining Therapy) (OTHER), No Counseling (OTHER), Placebo Sound Therapy (OTHER).
Who is sponsoring clinical trial NCT00890526?
This trial is sponsored by University of Alabama, Tuscaloosa, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00890526's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia